Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)
Stopped early · Phase 1
Conditions studied: Head and Neck Cancer
In brief
The purpose of this study is to evaluate the tolerability and safety of Xevinapant when added to weekly cisplatin-based concurrent chemoradiotherapy (CRT) in the treatment of participants with unresectable locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy.
Key facts
- Study ID
- NCT06056310
- Run by
- EMD Serono Research & Development Institute, Inc.
- People needed
- 18
- Starts
- 2024-01-18
- Expected to finish
- 2024-08-20
- Last updated by the study team
- 2025-09-29
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Participants having an Eastern Cooperative Oncology Group Performance Score (ECOG PS) of 0 - 1
- Histologically confirmed diagnosis in previously untreated Locally Advanced Squamous Cell Carcinoma of Head and neck (LA SCCHN) patient (Stage III, IVA, or IVB according to the American Joint Committee on Cancer [AJCC]/ Tumor Nodes and metastases (TNM) Staging System, 8th Edition) suitable for definitive Chemoradiotherapy (CRT), with one of the following primary sites: oropharynx (OPC) Human Papillomavirus (HPV)-negative, hypopharynx, and larynx
- Participant should be able to swallow liquids or has an adequately functioning feeding tube, gastrostomy, or jejunostomy in place. For participants requiring liquid nutrition at baseline or during the study including the follow-up period, access to liquid nutrition supply should be ensured
- Participant with evaluable tumor burden (measurable and/or non-measurable tumor lesions) assessed by CT scan and/or MRI, based on RECIST v 1.1.
- Adequate hematological, hepatic, and renal function as defined in the protocol
- Other protocol defined inclusion criteria could apply
You may not qualify if…
- Primary tumor of nasopharyngeal, paranasal sinuses, nasal, or oral cavity, salivary, thyroid, or parathyroid gland pathologies, skin, or unknown primary site
- Metastatic disease (Stage IVC as per AJCC/TNM, 8th Edition)
- Existing need of a hearing aid or greater than or equal to (>=) 25 decibel shift over 2 contiguous frequencies on a pretreatment hearing test as clinically indicated
- Known history of infection with human immunodeficiency virus (HIV). If unknown history of HIV, an HIV screening test is to be performed and participants with positive serology for HIV-1/2 must be excluded
- Known gastrointestinal disorder with clinically established malabsorption syndrome and major gastrointestinal surgery in the last 12 months that may limit oral absorption
- Other protocol defined exclusion criteria could apply
Where it is running
- Mount Sinai Comprehensive Cancer Center — Miami Beach, Florida, United States
- Karmanos Cancer Institute - PARENT — Detroit, Michigan, United States
- Montefiore Medical Center PRIME — The Bronx, New York, United States
- Cleveland Clinic — Cleveland, Ohio, United States
- Avera McKennan Hospital and University Health Center — Sioux Falls, South Dakota, United States
- Uza - Parent — Edegem, Belgium
- Universitair Ziekenhuis Gent - Medical Oncology — Ghent, Belgium
- Centre Hospitalier de l'Ardenne - PARENT — Libramont, Belgium
- Vitaz — Sint-Niklaas, Belgium
- Hadassah University Hospital - Ein Kerem — Jerusalem, Israel
- Pusan National University Hospital — Busan, South Korea
- Seoul National University Bundang Hospital — Seongnam, South Korea
- Konkuk University Medical Center — Seoul, South Korea
- Severance Hospital Yonsei University Health System — Seoul, South Korea
- Pusan National University Yangsan Hospital — Yangsan, South Korea
- ICO Girona - Hospital Universitari de Girona Dr Josep Trueta - Servicio de Oncologia Medica — Girona, Spain
- Clinica Universidad de Navarra (MAD) - Oncology Service — Madrid, Spain
- Hospital Universitario Fundacion Jimenez Diaz - Oncology — Madrid, Spain
- Hospital Universitario Virgen del Rocio - Oncology Service — Seville, Spain
- Kaohsiung Medical University Chung-Ho Memorial Hospital — Kaohsiung City, Taiwan
- China Medical University Hospital — Taichung, Taiwan
- National Taiwan University Hospital — Taipei, Taiwan
- Taipei Veterans General Hospital — Taipei, Taiwan
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.